Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer

Gefitinib (‘Iressa’, ZD1839) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated antitumour activity and favourable tolerability in Phase II studies. We investigated whether EGFR expression levels could predict for response to gefitinib in pati...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Parra, H S, Cavina, R, Latteri, F, Zucali, P A, Campagnoli, E, Morenghi, E, Grimaldi, G C, Roncalli, M, Santoro, A
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2004
Onderwerpen:
Clinical
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409824/
https://ncbi.nlm.nih.gov/pubmed/15187994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601923
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items